Novartis Home
At Novartis, we are reimagining medicine
Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond
ESG - Committed to increasing access
Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.
Environmental, Social and Governance (ESG)
Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen.
Novartis COVID-19 Information Center
Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.
Novartis at ESMO
Find the latest oncology resources on Novartis data featured at the European Society for Medical Oncology (ESMO).
AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy
Our commitment to doing what's right
Novartis is committed to ensuring our associates are empowered to do what’s right. On September 01, 2020, we introduced a new Code of Ethics for Novartis.